Matthew Meyerson
, Executive Director · Mass General Brigham
Credentials: · · ·
History
- Present
Center for Cancer Genomics · Mass General Brigham
- Present
Pathology-Anatomic and Clinical
Research
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
Science · 2004 · Last of 17 authors · 7,995 citations
Signatures of mutational processes in human cancer
Nature · 2013 · 7,793 citations
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Nature · 2012 · 6,204 citations
57 papers · 8 as a fellow
- LG
48 papers
40 papers · 1 as a fellow
- WS
35 papers
34 papers · 1 as a fellow
32 papers
31 papers
- BJ
29 papers
Grants
- 2015–2028
Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery
National Cancer Institute · R35
Contact PI · $12.4M · Dana-Farber Cancer Inst
- 2012–2023
Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma
National Cancer Institute · P01
Contact PI · $17.8M · Dana-Farber Cancer Inst
- 2006–2023
Inhibitor-Sensitive and -Resistant EGFR Mutants from Lung Cancer and Glioblastoma
National Cancer Institute · R01
Contact PI · $5.1M · Dana-Farber Cancer Inst
- 2009–2016
Genome Characterization Center (GCC)
National Cancer Institute · U24
Contact PI · $17M · Broad Institute, Inc.